|
1.
|
|
16 p, 3.8 MB |
Genetic and phenotypic attributes of splenic marginal zone lymphoma
/
Bonfiglio, Ferdinando (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bruscaggin, Alessio (Institute of Oncology Research, Bellinzona, Switzerland) ;
Guidetti, Francesca (Institute of Oncology Research, Bellinzona, Switzerland) ;
Terzi di Bergamo, Lodovico (Institute of Oncology Research, Bellinzona, Switzerland) ;
Faderl, Martin (Institute of Oncology Research, Bellinzona, Switzerland) ;
Spina, Valeria (Institute of Oncology Research, Bellinzona, Switzerland) ;
Condoluci, Adalgisa (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bonomini, Luisella (International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) ;
Forestieri, Gabriela (Institute of Oncology Research, Bellinzona, Switzerland) ;
Koch, Ricardo (Institute of Oncology Research, Bellinzona, Switzerland) ;
Piffaretti, Deborah (Institute of Oncology Research, Bellinzona, Switzerland) ;
Pini, Katia (Institute of Oncology Research, Bellinzona, Switzerland) ;
Pirosa, Maria Cristina (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Cittone, Micol Giulia (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Arribas, Alberto (Lymphoma Genomics, Institute of Oncology Research, Bellinzona, Switzerland) ;
Lucioni, Marco (Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Pavia, Italy) ;
Ghilardi, Guido (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.) ;
Wu, Wei (Institute of Oncology Research, Bellinzona, Switzerland) ;
Arcaini, Luca (University of Pavia, Pavia, Italy.) ;
Baptista, Maria Joao (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bastidas-Mora, Gabriela (Hospital Clínic i Provincial de Barcelona) ;
Bea, Sílvia (Hospital Clínic i Provincial de Barcelona) ;
Boldorini, Renzo (University of Eastern Piedmont, Novara, Italy) ;
Broccoli, Alessandro (IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.) ;
Buehler, Marco Matteo (University Hospital Zurich, Switzerland) ;
Canzonieri, Vincenzo (Pathology Unit, CRO Aviano National Cancer Institute, Aviano, Italy) ;
Cascione, Luciano (Institute of Oncology Research, Bellinzona, Switzerland) ;
Ceriani, Luca (Clinic of Nuclear Medicine and PET-CT Centre, Imaging Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Cogliatti, Sergio (Institute of Pathology, Kantonsspital St Gallen, St Gallen, Switzerland) ;
Corradini, Paolo (Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) ;
Derenzini, Enrico (European Institute of Oncology (IEO) IRCCS, Milan, Italy) ;
Devizzi, Liliana (Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy) ;
Dietrich, Sascha (University Hospital Heidelberg, Germany) ;
Elia, Angela Rita (Institute of Oncology Research, Bellinzona, Switzerland) ;
Facchetti, Fabio (Pathology Unit, Spedali Civili, Brescia, Italy) ;
Gaidano, Gianluca (University of Eastern Piedmont, Novara, Italy) ;
Garcia, Juan Fernando (MD Anderson Cancer Center, Madrid) ;
Gerber, Bernhard (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy) ;
Gomes da Silva, Maria (Instituto Português de Oncologia de Lisboa, Portugal) ;
Gritti, Giuseppe (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy) ;
Guidetti, Anna (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy) ;
Hitz, Felicitas (Kantonsspital St Gallen, St Gallen, Switzerland) ;
Inghirami, Giorgio (Weill Cornell Medical College, New York) ;
Ladetto, Marco (Azienda Ospedaliera SS Antonio e Biagio, Alessandria, Italy) ;
Lopez-Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Lucchini, Elisa (Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy) ;
Maiorana, Antonino (Universitá degli Studi di Modena e Reggio Emilia, Modena, Italy) ;
Marasca, Roberto (University of Modena and Reggio Emilia, Modena, Italy) ;
Matutes, Estella (Hospital Clínic i Provincial de Barcelona) ;
Meignin, Veronique (Saint Louis Hospital, Paris, France) ;
Merli, Michele (University of Insubria and ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy) ;
Moccia, Alden (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Mollejo, Manuela (Hospital Virgen de la Salud (Toledo)) ;
Montalban, Carlos (MD Anderson Cancer Center, Madrid) ;
Novak, Urban (University of Bern, Bern, Switzerland) ;
Oscier, David Graham (University Hospitals Dorset, Bournemouth, United Kingdom) ;
Passamonti, Francesco (University of Insubria) ;
Piazza, Francesco (Ospedale Universitario di Padova, Italy) ;
Pizzolitto, Stefano (General Hospital S Maria della Misericordia, Udine, Italy) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy) ;
Sabattini, Elena (University of Bologna, Italy) ;
Salles, Gilles (Université de Lyon, France) ;
Santambrogio, Elisa (Candiolo Cancer Institute (FPO-IRCCS), Candiolo, Turin, Italy) ;
Scarfò, Lydia (IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy) ;
Stathis, Anastasios (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Stüssi, Georg (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Geyer, Julia T. (Weill Cornell Medical College, New York) ;
Tapia, G. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tarella, Corrado (European Institute of Oncology (IEO) IRCCS, Milan, Italy) ;
Thieblemont, Catherine (Université de Paris, France) ;
Tousseyn, Thomas (University Hospitals Leuven, Belgium) ;
Tucci, Alessandra (Spedali Civili, Brescia, Italy.) ;
Vanini, Giorgio (University of Bern, Switzerland) ;
Visco, Carlo (University of Verona, Italy) ;
Vitolo, Umberto (Candiolo Cancer Institute (FPO-IRCCS), Candiolo, Turin, Italy) ;
Walewska, Renata (University Hospitals Dorset, Bournemouth, United Kingdom) ;
Zaja, Francesco (Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy) ;
Zenz, Thorsten (University Hospital Zurich, Switzerland) ;
Zinzani, Pier Luigi (Università di Bologna, Italy) ;
Khiabanian, Hossein (Rutgers University, New Brunswick) ;
Calcinotto, Arianna (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bertoni, Francesco (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bhagat, Govind (Columbia University, New York, USA) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
de Leval, Laurence (Institut Universitaire de Pathologie, Lausanne, Switzerland) ;
Dirnhofer, Stefan (University Hospital Basel (Basilea, Suïssa)) ;
Pileri, Stefano A. (European Institute of Oncology IRCCS, Milan, Italy) ;
Piris, Miguel Angel (Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid) ;
Traverse-Glehen, Alexandra (Centre Hospitalier Lyon Sud, Lyon, France) ;
Tzankov, Alexander (University Hospital Basel (Basilea, Suïssa)) ;
Paulli, Marco (Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Italy) ;
Ponzoni, Maurilio (Ateneo Vita-Salute San Raffaele University and Pathology Unit San Raffaele Scientific Institute, Milan, Italy) ;
Mazzucchelli, Luca (antonal Institute of Pathology, Locarno, Switzerland) ;
Cavalli, Franco (Institute of Oncology Research, Bellinzona, Switzerland; and.) ;
Zucca, Emanuele (International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) ;
Rossi, Davide (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Universitat Autònoma de Barcelona
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are diverse. [...]
2022 -  10.1182/blood.2021012386
Blood, Vol. 139 Núm. 5 (february 2022) , p. 732-747
|
|
|
2.
|
|
1 p, 825.9 KB |
Correction : Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
/
Mansouri, Larry (Karolinska Institutet (Estocolm, Suècia)) ;
Thorvaldsdottir, Birna (Karolinska Institutet (Estocolm, Suècia). Department of Molecular Medicine and Surgery) ;
Sutton, Lesley-Ann (Karolinska Institutet (Estocolm, Suècia)) ;
Karakatsoulis, Georgios (University of Ioannina) ;
Meggendorfer, Manja (MLL Munich Leukemia Laboratory) ;
Parker, Helen (University of Southampton) ;
Nadeu, Ferran (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Brieghel, Christian (Copenhagen University Hospital) ;
Laidou, Stamatia (Institute of Applied Biosciences) ;
Moia, Riccardo (Università del Piemonte Orientale) ;
Rossi, Davide (Institute of Oncology Research) ;
Catherwood, Mark (Queen's University Belfast) ;
Kotaskova, Jana (Masaryk University) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Rodríguez-Vicente, Ana E. (Universidad de Salamanca) ;
Benito, Rocío (Universidad de Salamanca) ;
Rigolin, Gian Matteo (University of Ferrara) ;
Bonfiglio, Silvia (Università Vita Salute San Raffaele) ;
Scarfo, Lydia (Università Vita Salute San Raffaele) ;
Mattsson, Mattias (Uppsala University) ;
Davis, Zadie (University Hospitals Dorset) ;
Gogia, Ajay (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Rani, Lata (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Baliakas, Panagiotis (Uppsala University) ;
Foroughi-Asl, Hassan (Karolinska Institutet (Estocolm, Suècia)) ;
Jylhä, Cecilia (Karolinska Institutet (Estocolm, Suècia)) ;
Skaftason, Aron (Karolinska Institutet (Estocolm, Suècia)) ;
Rapado, Inmaculada (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Miras, Fatima (Hospital Universitario 12 de Octubre (Madrid)) ;
Martinez-Lopez, Joaquín (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
de la Serna, Javier (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Rivas, Jesús María Hernández (Universidad de Salamanca) ;
Thornton, Patrick (Beaumont Hospital (Dublín, Irlanda)) ;
Larráyoz, María José (Universidad de Navarra) ;
Calasanz, M.J (Universidad de Navarra) ;
Fésüs, Viktória (Semmelweis University) ;
Mátrai, Zoltán (Central Hospital of Southern Pest-National Institute of Hematology and Infectious Diseases (Budapest, Hongria)) ;
Bödör, Csaba (Semmelweis University) ;
Smedby, Karin E. (Karolinska Institutet (Estocolm, Suècia)) ;
Espinet, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gupta, Ritu (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Bullinger, Lars (Charité - Universitätsmedizin Berlin) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Tazón-Vega, Bárbara (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Baran-Marszak, Fanny (Hôpital Avicenne AP-HP) ;
Oscier, David (University Hospitals Dorset) ;
Nguyen-Khac, Florence (Sorbonne University) ;
Zenz, Thorsten (University Hospital of Zurich) ;
Terol, Maria Jose (Universitat de València) ;
Cuneo, Antonio (University of Ferrara) ;
Hernández-Sánchez, María (Universidad de Salamanca) ;
Pospisilova, Sarka (Masaryk University) ;
Mills, Ken (Queen's University Belfast) ;
Gaidano, Gianluca (Università del Piemonte Orientale) ;
Niemann, Carsten U. (Copenhagen University Hospital) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
Strefford, Jonathan C. (University of Southampton) ;
Ghia, Paolo (Università Vita Salute San Raffaele) ;
Stamatopoulos, Kostas (Institute of Applied Biosciences) ;
Rosenquist, Richard (Karolinska University Hospital and Karolinska Institutet (Suècia))
2023 - 10.1038/s41375-023-01813-3
Leukemia, Vol. 37 (january 2023) , p. 504
|
|
|
3.
|
|
9 p, 1.7 MB |
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status : a study by ERIC in HARMONY
/
Mansouri, Larry (Karolinska Institutet (Estocolm, Suècia)) ;
Thorvaldsdottir, Birna (Karolinska Institutet (Estocolm, Suècia)) ;
Sutton, Lesley-Ann (Karolinska Institutet (Estocolm, Suècia)) ;
Karakatsoulis, Georgios (University of Ioannina. Department of Mathematics) ;
Meggendorfer, Manja (MLL Munich Leukemia Laboratory) ;
Parker, Helen (University of Southampton) ;
Nadeu, Ferran (Centro de Investigación Biomédica en Red de Cáncer) ;
Brieghel, Christian (Copenhagen University Hospital. Department of Hematology, Rigshospitalet) ;
Laidou, Stamatia (Centre for Research and Technology Hellas (Tessalònica, Grècia)) ;
Moia, Riccardo (Università del Piemonte Orientale) ;
Rossi, Davide (Institute of Oncology Research (Suïssa)) ;
Catherwood, Mark (Queen's University Belfast) ;
Kotaskova, Jana (Masaryk University) ;
Delgado, Julio (Universitat de Barcelona) ;
Rodríguez-Vicente, Ana E. (Hospital Universitario de Salamanca) ;
Benito, Rocío (Hospital Universitario de Salamanca) ;
Rigolin, Gian Matteo (University of Ferrara) ;
Bonfiglio, Silvia (Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Scarfo, Lydia (Università Vita Salute San Raffaele) ;
Mattsson, Mattias (Uppsala University. Department of Immunology, Genetics and Pathology) ;
Davis, Zadie (Molecular Pathology Department, University Hospitals Dorset) ;
Gogia, Ajay (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Rani, Lata (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Baliakas, Panagiotis (Uppsala University. Department of Immunology, Genetics and Pathology) ;
Foroughi-Asl, Hassan (Karolinska Institutet (Estocolm, Suècia)) ;
Jylhä, Cecilia (Karolinska Institutet (Estocolm, Suècia)) ;
Skaftason, Aron (Karolinska Institutet (Estocolm, Suècia)) ;
Rapado, Inmaculada (Spanish National Cancer Research) ;
Miras, Fatima (Hospital Universitario 12 de Octubre (Madrid)) ;
Martinez-Lopez, Joaquín (Spanish National Cancer Research) ;
de la Serna, Javier (Spanish National Cancer Research) ;
Rivas, Jesús María Hernández (Hospital Universitario de Salamanca) ;
Thornton, Patrick (Beaumont Hospital. Haematology Department) ;
Larráyoz, María José (Instituto de Investigación Sanitaria de Navarra) ;
Calasanz, M.J (Instituto de Investigación Sanitaria de Navarra) ;
Fésüs, Viktória (Semmelweis University) ;
Mátrai, Zoltán (Central Hospital of Southern Pest-National Institute of Hematology and Infectious Diseases, Budapest, Hungary) ;
Bödör, Csaba (Semmelweis University) ;
Smedby, Karin E. (Karolinska Institutet (Suècia). Department of Medicine Solna) ;
Espinet, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gupta, Ritu (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Bullinger, Lars (Charité - Universitätsmedizin Berlin) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Tazón-Vega, Bárbara (Vall d'Hebron Institut d'Oncologia) ;
Baran-Marszak, Fanny (Service d'hématologie Biologique Hôpital Avicenne Assistance Publique des Hôpitaux de Paris) ;
Oscier, David (University Hospitals Dorset) ;
Nguyen-Khac, Florence (Sorbonne University) ;
Zenz, Thorsten (University Hospital and University of Zurich. Department of Oncology and Haematology) ;
Terol, Maria Jose (University of Valencia. Department of Hematology) ;
Cuneo, Antonio (University of Ferrara. Hematology-Department of Medical Sciences) ;
Hernández-Sánchez, María (Hospital Universitario de Salamanca) ;
Pospisilova, Sarka (Masaryk University. Central European Institute of Technology) ;
Mills, Ken (Queen's University Belfast) ;
Gaidano, Gianluca (Università del Piemonte Orientale) ;
Niemann, Carsten U. (Copenhagen University Hospital) ;
Campo, Elias (Universitat de Barcelona) ;
Strefford, Jonathan C. (University of Southampton) ;
Ghia, Paolo (Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Stamatopoulos, Kostas (Institute of Applied Biosciences (Grècia)) ;
Rosenquist, Richard (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Universitat Autònoma de Barcelona
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. [...]
2022 - 10.1038/s41375-022-01802-y
Leukemia, Vol. 37 (december 2022) , p. 339-347
|
|
|
4.
|
|
13 p, 1.6 MB |
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
/
Arribas, Alberto J (SIB Swiss Institute of Bioinformatics) ;
Napoli, Sara (Università della Svizzera Italiana) ;
Cascione, Luciano (SIB Swiss Institute of Bioinformatics) ;
Sartori, Giulio (Università della Svizzera Italiana) ;
Barnabei, Laura (Università della Svizzera Italiana) ;
Gaudio, Eugenio (Università della Svizzera Italiana) ;
Tarantelli, Chiara (Università della Svizzera Italiana) ;
Mensah, Afua Adjeiwaa (Università della Svizzera Italiana) ;
Spriano, Filippo (Università della Svizzera Italiana) ;
Zucchetto, Antonella (Centro di Riferimento Oncologico di Aviano) ;
Rossi, Francesca M (Centro di Riferimento Oncologico di Aviano) ;
Rinaldi, Andrea (Università della Svizzera Italiana) ;
Castro de Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jovic, Sandra (Università della Svizzera italiana) ;
Bordone-Pittau, Roberta (Oncology Institute of Southern Switzerland) ;
Di Veroli, Alessandra (University of Perugia) ;
Stathis, Anastasios (Università della Svizzera Italiana) ;
Cruciani, Gabriele (University of Perugia) ;
Stussi, Georg (Oncology Institute of Southern Switzerland) ;
Gattei, Valter (Centro di Riferimento Oncologico di Aviano) ;
Brown, Jennifer R (Harvard Medical School) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zucca, Emanuele (Oncology Institute of Southern Switzerland) ;
Rossi, Davide (Oncology Institute of Southern Switzerland) ;
Bertoni, Francesco (Oncology Institute of Southern Switzerland) ;
Universitat Autònoma de Barcelona
PI3Kδ inhibitors are active in patients with lymphoid neoplasms and a first series of them have been approved for the treatment of multiple types of B-cell lymphoid tumors, including marginal zone lymphoma (MZL). [...]
2022 - 10.3324/haematol.2021.279957
Haematologica, Vol. 107 Núm. 11 (november 2022) , p. 2685-2697
|
|
|
5.
|
|
15 p, 1.5 MB |
Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O· production in cancer cells
/
Cordani, Marco (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ;
Butera, Giovanna (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Dando, Ilaria (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Torrens-Mas, Margalida (Institut d'Investigació Sanitària de Palma) ;
Butturini, Elena (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Pacchiana, Raffaella (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Oppici, Elisa (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Cavallini, Chiara (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ;
Gasperini, Sara (Section of General Pathology, University of Verona. Department of Medicine) ;
Tamassia, Nicola (Section of General Pathology, University of Verona. Department of Medicine) ;
Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ;
Coan, Michela (National Cancer Institute (Aviano, Itàlia)) ;
Rossi, Davide (Institute of Oncology Research) ;
Gaidano, Gianluca (University of Eastern Piedmont. Division of Hematology, Department of Translational Medicine) ;
Caraglia, Michele (Department of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy) ;
Mariotto, Sofia (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Spizzo, Riccardo (National Cancer Institute (Aviano, Itàlia)) ;
Roca, Pilar (Institut d'Investigació Sanitària de Palma) ;
Oliver, Jordi (Institut d'Investigació Sanitària de Palma) ;
Scupoli, Maria Teresa (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ;
Donadelli, Massimo (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Universitat Autònoma de Barcelona
The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function isoforms actively promote cancer malignancy. A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status. [...]
2018 - 10.1038/s41416-018-0288-2
British Journal of Cancer, Vol. 119 (october 2018) , p. 994-1008
|
|
|
6.
|
|
8 p, 788.7 KB |
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
/
Hájek, R. (University Hospital Ostrava) ;
Masszi, T. (St László Hospital (Hongria)) ;
Petrucci, M. T. (Sapienza Università di Roma) ;
Palumbo, A. (Università di Torino) ;
Rosiñol, L. (Hospital Clínic i Provincial de Barcelona) ;
Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ;
Yong, K. L. (University College London Cancer Institute) ;
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Minarik, J. (University Hospital Olomouc (Olomouc, República Txeca)) ;
Pour, L. (University Hospital Ostrava) ;
Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ;
Maisnar, V. (Charles University. Faculty of Medicine in Hradec Králové) ;
Rossi, Davide (Amedeo Avogadro University of Eastern Piedmont) ;
Kasparu, H. (Ordensklinikum Linz Elisabethinen) ;
Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ;
Yehuda, D. B. (Hadassah Medical Center, Jerusalem, Israel) ;
Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ;
Jenner, M. (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ;
Dávid, M. (University of Pécs, Hungary) ;
de la Rubia, Javier (Hospital Universitari i Politècnic La Fe (València)) ;
Drach, J. (Medical University of Vienna) ;
Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ;
Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ;
Leleu, Xavier (Hopital Huriez, CHRU, Lille, France) ;
Munder, M. (University Medicine Mainz, Germany) ;
Offidani, M. (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ;
Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ;
Rajangam, K. (Onyx Pharmaceuticals, Inc.) ;
Chang, Y. L. (Onyx Pharmaceuticals, Inc.) ;
San-Miguel, J. F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Ludwig, H. (Wilhelminen Cancer Research Institute (Viena, Àustria))
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114
|
|
|
7.
|
|
11 p, 693.2 KB |
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
/
Malcikova, J. (Brno, Czech Republic) ;
Tausch, E. (Ulm, Germany) ;
Rossi, Davide (Bellinzona, Switzerland) ;
Sutton, L. A. (Stockholm, Sweden) ;
Soussi, T. (Stockholm, Sweden) ;
Zenz, Thorsten (Zürich, Switzerland) ;
Kater, A. P. (Amsterdam, The Netherlands) ;
Niemann, C. U. (Copenhagen, Denmark) ;
González De Castro, David (Belfast, UK) ;
Davi, F. (Paris, France) ;
Gonzalez Diaz, M. (Salamanca, Spain) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Gaidano, Gianluca (Novara, Italy) ;
Stamatopoulos, K. (Thessaloniki, Greece) ;
Rosenquist, R. (Stockholm, Sweden) ;
Stilgenbauer, S. (Ulm, Germany) ;
Ghia, Paolo (Milan, Italy) ;
Pospisilova, S. (Brno, Czech Republic) ;
Universitat Autònoma de Barcelona
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. [...]
2018 - 10.1038/s41375-017-0007-7
Leukemia, Vol. 32 (february 2018) , p. 1070-1080
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
